The US NIH is stepping back from 'top-down' science.
My latest analysis for @nature.com shows that funding calls have plummeted by 90%, funneling billions into broad, 'investigator-initiated' ideas, rather than targeted, agency-driven ones.
A massive shift for the American biomedical enterprise.
US biomedical funding behemoth says the approach will boost innovation, but some researchers worry that understudied areas of science will suffer.
